Precision Exercise Using Myostatin/Follistatin Ratio in Obese Adults (PRECISION-MASL)

November 18, 2026 updated by: Diabetes Foundation, India

A Precision Exercise Approach Using Myostatin/Follistatin Ratio Stratification to Improve Lean Body Mass and Metabolic Health: A 12-Month Randomized Clinical Trial in Obese North Indian Adults

This study evaluates whether a 12-month supervised progressive resistance training program improves lean body mass and metabolic health in obese North Indian adults aged 35-60 years. Asian Indians are uniquely predisposed to sarcopenic obesity-the coexistence of excess body fat and reduced muscle mass-which significantly increases the risk of type 2 diabetes and cardiovascular disease.

Participants will be stratified into High-Ratio and Low-Ratio groups based on their baseline Myostatin/Follistatin (MSTN/FST) ratio, an biological index of muscle catabolism versus growth. Half of the participants in each stratum will undergo a 12-month supervised resistance training program, while the other half will receive standard lifestyle advice. The primary goal is to determine whether baseline MSTN/FST ratio predicts the extent of muscle mass gain and whether reducing this ratio mediates improvements in insulin resistance and systemic inflammation.

Study Overview

Detailed Description

Background & Scientific Rationale: Sarcopenic obesity is a major driver of cardiometabolic risk in Asian Indians due to low baseline lean mass combined with high visceral adiposity. Myostatin (MSTN) acts as a primary negative regulator of muscle growth, whereas follistatin (FST) acts as its circulating antagonist. Previous genetic research demonstrates that gain-of-function Myostatin gene variants are strongly associated with lower lean body mass and increased adiposity in North Indians. This trial prospectively tests whether the serum MSTN/FST ratio functions as a precision biomarker to stratify exercise response and guide targeted exercise interventions.

Study Objectives:

Determine the efficacy of a 12-month supervised resistance training program on total lean body mass (LBM) and physical performance compared to lifestyle control, testing for treatment interaction across baseline MSTN/FST strata.

Characterize the molecular adaptations of the myostatin axis by measuring serum myostatin, follistatin, MSTN/FST ratio, and peripheral blood mononuclear cell (PBMC) MSTN mRNA expression at baseline and 12 months.

Assess whether reductions in the MSTN/FST ratio mediate improvements in insulin resistance (HOMA-IR), systemic inflammatory markers (IL-6, TNF-α, hsCRP), and muscle quality.

Trial Design & Interventions: A single-center, ratio-stratified, 1:1 parallel-group randomized controlled superiority trial of 200 obese North Indian adults.

Resistance Training Arm (n=100): 3 supervised sessions per week (60 minutes per session) at 70-80% 1-repetition maximum (1RM) using progressive resistance overload reassessed every 8 weeks.

Control Arm (n=100): Standard individualized dietary and physical activity advice per national guidelines without supervised exercise sessions.

Outcome Assessments: Dual-energy X-ray absorptiometry (DEXA) for total LBM, appendicular lean mass, and body fat percentage; handgrip dynamometry and 1RM testing for strength; quantitative ELISA for serum biomarkers; real-time qRT-PCR (2-ΔΔCt method) for PBMC MSTN mRNA expression; and standardized biochemical panels for glycemic and inflammatory profiles.

Study Type

Interventional

Enrollment (Estimated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110016
        • Diabetes Foundation India
        • Contact:
        • Principal Investigator:
          • Professor Anoop Misra, MD
        • Sub-Investigator:
          • Dr Surya Prakash Bhatt, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 35-60 years inclusive
  • BMI ≥ 25 kg/m² (Asian Indian cut-off for overweight)
  • Body fat percentage ≥ 30% in women or ≥ 25% in men measured by DEXA
  • Sedentary lifestyle, defined as less than 150 minutes per week of moderate-intensity physical activity by self-report and validated by wearable activity tracker at screening
  • Non-diabetic (fasting plasma glucose < 126 mg/dL and HbA1c < 6.5%)
  • Willing and able to provide written informed consent
  • Resident within 25 km of Fortis C-DOC for the full 12-month trial duration

Exclusion Criteria:

  • Known Type 2 Diabetes Mellitus
  • Established cardiovascular disease, heart failure, cerebrovascular accident, or peripheral arterial disease
  • Chronic kidney disease
  • Active malignancy or history of malignancy within 5 years
  • Use of anabolic steroids, systemic corticosteroids, growth hormone, or immunosuppressants within 3 months of enrolment
  • Any musculoskeletal, neurological, or orthopaedic condition precluding participation in supervised resistance training
  • Pregnancy or lactation
  • Participation in any structured supervised exercise programme in the preceding 6 months
  • HIV infection or other active chronic infection
  • Thyroid disorder not on stable replacement therapy for at least 3 months
  • Severe end-organ damage
  • Inability to provide informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Progressive Resistance Training

Supervised progressive resistance training program consisting of 3 sessions per week for 12 months (60 minutes per session) at 70-80% 1-repetition maximum (1RM). Includes multi-joint upper and lower body exercises (leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest/overhead press, crunches) with formal load reassessment every 8 weeks.

12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.

A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.

Active Comparator: Standard Lifestyle Advice

A single structured 60-minute lifestyle counseling session at baseline providing individualized dietary advice and physical activity recommendations based on ICMR national guidelines for Asian Indians, along with educational materials and follow-up assessments at 6 and 12 months.

12-month supervised progressive resistance training program, 3 sessions per week (60 min/session) at 70-80% 1-repetition maximum (1RM) featuring progressive overload reassessed every 8 weeks. Includes leg press, knee extension/flexion, hip abduction, lat pulldown, seated row, chest press, overhead press, and abdominal crunches.

A single 60-minute structured lifestyle counseling session at baseline providing individualized dietary and physical activity advice according to ICMR consensus guidelines for Asian Indians, supplemented with written educational materials.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage change in total lean body mass
Time Frame: Baseline, 6 months, 12 months

Percentage change in total lean body mass (LBM) from baseline to 6 and 12 months measured by DEXA, comparing the resistance training and control groups and assessing differences between High-Ratio and Low-Ratio MSTN/FST strata.

Baseline, 6 months, 12 months
Change in Serum Myostatin Concentration
Time Frame: Baseline, 12 months

Change in serum myostatin levels quantified in duplicate via validated sandwich ELISA (intra-assay CV < 8%, inter-assay CV < 10%).

Baseline, 12 months
Change in Serum Follistatin Concentration
Time Frame: Baseline, 12 months

Change in serum follistatin levels quantified in duplicate via validated sandwich ELISA

Baseline, 12 months
Change in Serum Myostatin/Follistatin (MSTN/FST) Ratio
Time Frame: Baseline, 12 months

Integrated dynamic index of anabolic-catabolic balance calculated as serum myostatin (pg/mL) divided by serum follistatin (pg/mL).

Baseline, 12 months
Change in PBMC MSTN mRNA Expression
Time Frame: Baseline, 12 months

Relative gene expression of myostatin mRNA isolated from Peripheral Blood Mononuclear Cells (PBMCs) and measured via real-time quantitative PCR using the Livak 2 -ΔΔCT method normalized to GAPDH.

Baseline, 12 months
Change in Systemic Inflammatory Markers
Time Frame: Baseline, 6 months, 12 months

Quantification of circulating serum Interleukin-6 (IL-6; pg/mL), Tumor Necrosis Factor-alpha (TNF-α; pg/mL), and high-sensitivity C-Reactive Protein (hsCRP; mg/L) via high-sensitivity immunoassay methods.

Baseline, 6 months, 12 months
Change in Skeletal Muscle Quality
Time Frame: Baseline, 6 months, 12 months

Evaluation of muscle quality calculated as DEXA-derived muscle mass relative to strength, combined with ultrasound assessment of quadriceps muscle thickness and echo intensity.

Baseline, 6 months, 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Appendicular Lean Mass (ASMI)
Time Frame: Baseline, 6-month, and 12-month.

Measured by DEXA (kg/m²)

Baseline, 6-month, and 12-month.
Handgrip Strength
Time Frame: Baseline, 6-month, and 12-month.

Measured using a calibrated hand dynamometer (kg)

Baseline, 6-month, and 12-month.
Lower-Body Muscle Strength
Time Frame: Baseline, 6-month, and 12-month.

Measured by 1-repetition maximum (1RM) in leg press (kg)

Baseline, 6-month, and 12-month.
Gait Speed
Time Frame: Baseline, 6-month, and 12-month.

Measured by 4-metre timed walk test (seconds or m/s)

Baseline, 6-month, and 12-month.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Professor Anoop Misra, MD, Diabetes Foundation, India

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

November 30, 2029

Study Completion (Estimated)

November 30, 2029

Study Registration Dates

First Submitted

August 24, 2026

First Submitted That Met QC Criteria

November 18, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 18, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe